Project Grant R01CA291986
Award Date
4/9/25
Completion Date
3/31/30
Dollars Obligated
$509K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
The federal Project Grant award of $371,719 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research at the University of Pennsylvania to investigate the role of the epigenetic modifier NSD2 in prostate cancer progression. The primary aims are to gain deeper mechanistic understanding of how NSD2 influences the chromatin landscape to facilitate the assembly of the androgen receptor (AR) enhanceosome complex, and to evaluate...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) provides $564,543 to Weill Medical College of Cornell University to conduct research on understanding the role of the androgen receptor (AR) in prostate cancer. The research aims to determine the context that allows engagement of the AR's growth suppressive transcriptional programs in prostate cancer, establish the translational implications of oncogenic versus growth...
The National Cancer Institute (NCI) awarded a $386,866 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Regents of the University of Michigan to develop individualized estimates of treatment benefit from hormone therapy for men with prostate cancer. The project aims to integrate models for other-cause mortality risk, distant metastases, and prostate cancer-specific mortality to provide personalized estimates of treatment outcomes, and to develop a web...
This Federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Emory University aims to determine the molecular mechanisms underlying the transition of prostate cancer from a luminal to a neuroendocrine phenotype. The $1,082,472 award over a 5-year period from September 2024 to August 2029 will support research to understand how the transcription factor FOXA2 interacts with NKX2-1 to drive this transdifferentiation process, including the role...
This $415,902 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Massachusetts Boston to investigate the role of the FOXA2/AP-1 axis in driving lineage plasticity and therapy resistance in castration-resistant prostate cancer. The key objectives are to determine if FOXA2 expression can promote a multilineage transition state in luminal prostate cancer cells, examine how FOXA2 collaborates with AP-1 to drive lineage...
This $159,803 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support the Regents of the University of Michigan in developing and integrating emerging multi-omics technologies including genomics, transcriptomics, epigenomics, and proteomics to analyze advanced, rare, and pediatric cancers. The goal is to translate these new analytical approaches into clinically actionable information through the University's MI-ONCOSEQ CLIA...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $644,622 to the Regents of the University of Michigan to develop tools and predictive models for dosimetry-guided radioligand therapy (RLT) for metastatic castrate-resistant prostate cancer (mCRPC). The key objectives are: 1) developing a novel method for bone marrow dosimetry, 2) building models to predict absorbed dose from pre-therapy PET imaging and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Case Western Reserve University aims to advance the understanding of androgen receptor (AR) mechanisms in metastatic castration-resistant prostate cancer (mCRPC). The $606,869 award, effective from July 2024 to June 2029, will utilize sophisticated molecular biology and computational techniques to map the epigenetic mechanisms driving mCRPC tumor growth. The project will explore how small...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $1,031,313.00 to The Research Foundation For The State University Of New York, doing business as Stony Brook University, to investigate luminal plasticity and clonal expansions in the prostate during aging and cancer progression. The research aims to elucidate the role of a previously uncharacterized "luminal intermediate" (LUMI) cell population and its associated Wnt...
This federal Project Grant award for $472,458, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at the University of Texas Southwestern Medical Center to investigate the regulation of the PTPN1 gene and its role in the transition of prostate cancer cells to a therapy-resistant neuroendocrine phenotype. The key goals are to: 1) examine how anti-androgen therapy influences PTPN1 expression, 2) uncover the regulatory...